Happy Wednesday, Cannabis Investors! When it comes to cannabis, Switzerland isn’t just a neutral observer. The country just launched a cannabis study with 7,500 participants. Is it planning to follow its neighbor Germany’s lead and wade into legalization?

Also, check out the newest episode of Cannabis Insider, also available on Apple and Spotify.*

Puff Pass: Did someone forward you this email? Click here to get automatically subscribed.

TOP STORY

What's Going On With Marijuana Stocks Tilray And Canopy Growth?

Briefly: Tilray and Canopy Growth shares are trading higher to start the week with renewed optimism on the possibility of rescheduling.

So Basically: At a White House meeting Friday, Vice President Kamala Harris said that the DEA needs to move quickly to reschedule marijuana from a Schedule I to a Schedule III drug.

So Then: Cannabis stocks jumped on Friday and continued to climb on Monday following chatter regarding a possibly imminent rescheduling of marijuana by the Drug Enforcement Agency.

So What? For Tilray Brands, the 200-day moving average sits at $2.02, according to Benzinga Pro, which is above the current price of $1.88. Canopy Growth shares are up 4.96% at $4.02.

Click here to see what the Street expects for these stocks in 2024.

WHERE DEALS GET DONE

The Benzinga Cannabis Capital Conference is where deals get done.

With 2,000+ decision-makers in one room, attendees have the chance to engage in a year's worth of networking in just two days. More than 100 CEOs and 200 Investors confirmed for Investment and Branding on April 16th - 18th at The Diplomat Beach Resort in Hollywood, FL.

Boris Jordan, executive chairman of Curaleaf, to deliver Keynote Speech.

Don't be the ONLY cannabis leader missing this event.

ZINGERS

Controversial bill threatens Kentucky's medical marijuana program

Hawaiian lawmakers divided on weed legalization

Germany: Will cannabis legalization change the game?

Investing: Cannabis stock gainers and losers

South Dakota Governor Kristi Noem signs 3 medical marijuana bills into law, one placing 'guardrails' on former prisoners

ONE FOR THE ROAD

Cannabis And Guns: Legal Battle Heats Up As Feds Block Weapons Sales Over Weed Smell, Lawsuits Ensue

Briefly: Can weed users exercise their Second Amendment right? The debate rages on.

Back Up: Under federal law, it is illegal for anyone who uses cannabis to own a gun. The federal government argues weed can impair judgment and reaction time, potentially increasing the risk of accidents or misuse of firearms.

But Then: Critics argue this leads to unfair and discriminatory practices. For example, during a routine gun dealer audit, an ATF investigator stopped the sale of a handgun to a man solely because he allegedly smelled of marijuana.

So Then: The man, according to the Second Amendment Foundation, vehemently denied any cannabis use and said he'd already passed a background check. The ATF acknowledged the smell could have been secondhand smoke, raising questions about its justification.

Click here to read more.

WHERE DEALS GET DONE

The Benzinga Cannabis Capital Conference is where deals get done.

With 2,000+ decision-makers in one room, attendees have the chance to engage in a year's worth of networking in just two days. More than 100 CEOs and 200 Investors confirmed for Investment and Branding on April 16th - 18th at The Diplomat Beach Resort in Hollywood, FL.

Boris Jordan, executive chairman of Curaleaf, to deliver Keynote Speech.

Don't be the ONLY cannabis leader missing this event.

KEEP READING

Before you go, be sure to subscribe to our other newsletters:

Ring The Bell: If you have to pick just one daily financial newsletter, it’s not a choice. Subscribe here.

The Street Sheet: A Wall Street cheat sheet, delivered every Sunday directly to your inbox. One-click subscribe here.

Future Finance: TradFi is tired. Wake up to the future of finance with this midday fintech and crypto letter. Subscribe here.

The Flag: Top takes from Washington to Wall Street impacting policy and your portfolio. One-click subscribe here.